Innoviva

Innoviva Intangible Assets

The Intangible Assets of Innoviva (INVA) as of Oct 20, 2026 is 278.39 M USD. In the previous year, Intangible Assets was 314.12 M USD — a change of -11.37% (lower).

Intangible Assets

278.39 MUSD

YoY

-11.37%

Last updated:

Intangible Assets of Innoviva is 2024 278.39 M USD. Intangible Assets of Innoviva was 2023 314.12 M USD. It decreases by -11.37% lower compared to the previous year.

The Innoviva Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
166.70 M USD
Jan 1, 2018
152.90 M USD
Jan 1, 2019
139.10 M USD
Jan 1, 2020
125.30 M USD
Jan 1, 2021
111.40 M USD
Jan 1, 2022
350.50 M USD
Jan 1, 2023
314.12 M USD
Jan 1, 2024
278.39 M USD
The Innoviva Intangible Assets history
YEARIntangible AssetsYoY
278.39 MUSD-11.37%
314.12 MUSD-10.38%
350.50 MUSD+214.63%
111.40 MUSD-11.09%
125.30 MUSD-9.92%
139.10 MUSD-9.03%
152.90 MUSD-8.28%
166.70 MUSD-7.65%
180.50 MUSD-7.15%
194.40 MUSD-6.63%
208.20 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innoviva Stock analysis

What does Innoviva do? Innoviva Inc - An innovative story Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016. The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Business model of Innoviva Inc The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments. Divisions of Innoviva Inc Innoviva Inc is divided into three divisions: development, licensing, and financing. The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard. The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials. The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment. Products of Innoviva Inc Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include: - RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma - ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD - TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD These products have been developed by Innoviva Inc and are licensed to partner companies for distribution. Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innoviva stock

Intangible Assets of Innoviva is 278.39 M USD in 2024.

Intangible Assets of Innoviva changed from 314.12 M USD to 278.39 M USD, representing a -11.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Innoviva since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Innoviva historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Innoviva

All Key Metrics — Innoviva